

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MA9A8FBCA8DEEN.html>

Date: April 2020

Pages: 76

Price: US\$ 3,500.00 (Single User License)

ID: MA9A8FBCA8DEEN

Abstracts

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotrophic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with

respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 5 and 1 respectively.

Report covers products from therapy areas Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Central Nervous System, Genetic Disorders, Immunology, Musculoskeletal Disorders, Ophthalmology, Infectious Disease, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Porphyria (Erythropoietic Protoporphryri), Rheumatoid Arthritis, Uveitis, Vitiligo, Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19), Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

and enlists all their major and minor projects

The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development

Aequus BioPharma Inc

Clinuvel Pharmaceuticals Ltd

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Mitsubishi Tanabe Pharma Corp

Palatin Technologies Inc

SynAct Pharma AB

Viewpoint Molecular Targeting LLC

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles

afamelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dersimelagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Parvysmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize MCR1 for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-9643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or

MC1R) - Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones

Featured News & Press Releases

Apr 23, 2020: SCENESSE to be Prescribed in China

Apr 16, 2020: First US patients to be treated with SCENESSE

Apr 16, 2020: Innovative drug launched for rare, isolating, "light intolerance" disorder

Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in *Rheumatology and Therapy*

Apr 03, 2020: SynAct Pharma applies for patent for AP1189 within COVID-19

Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities

Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in *Kidney International Reports*

Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in *Open Access Rheumatology: Research and Reviews*

Mar 03, 2020: FDA meeting confirmed to advance SCENESSE in vitiligo

Mar 02, 2020: Supply of Scenesse unaffected by coronavirus

Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020

Feb 19, 2020: Palatin Technologies announces first patient enrolled in dry eye disease phase 2 clinical trial with PL9643

Feb 10, 2020: Request for FDA guidance meeting SCENESSE in Vitiligo

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aequus BioPharma Inc, H1 2020
Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
Pipeline by Eton Pharmaceuticals Inc, H1 2020
Pipeline by Mallinckrodt Plc, H1 2020
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
Pipeline by Palatin Technologies Inc, H1 2020
Pipeline by SynAct Pharma AB, H1 2020
Pipeline by Viewpoint Molecular Targeting LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aequus BioPharma Inc

Clinuvel Pharmaceuticals Ltd

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Mitsubishi Tanabe Pharma Corp

Palatin Technologies Inc

SynAct Pharma AB

Viewpoint Molecular Targeting LLC

I would like to order

Product name: Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MA9A8FBCA8DEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA9A8FBCA8DEEN.html>